Last reviewed · How we verify
PEG-IFN alfa-2a
PEG-IFN alfa-2a is a Small molecule drug developed by Hoffmann-La Roche. It is currently FDA-approved. Also known as: Pegasys, PEGASYS.
At a glance
| Generic name | PEG-IFN alfa-2a |
|---|---|
| Also known as | Pegasys, PEGASYS |
| Sponsor | Hoffmann-La Roche |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- VIR-2218 and Peginterferon Alfa-2a for Chronic Hepatitis B (PHASE2)
- Effect of Storytelling on Questionnaire Completion and Quality of Collected Data in an E-Cohort (NA)
- A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006) (PHASE3)
- DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma (PHASE1, PHASE2)
- Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma (PHASE1)
- Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV) (PHASE2)
- Efficacy and Safety of MP-424, Peginterferon Alfa-2a (PEG-IFN Alfa-2a), and Ribavirin(RBV) in Treatment-Naïve or Relapsed Hepatitis C (PHASE3)
- Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PEG-IFN alfa-2a CI brief — competitive landscape report
- PEG-IFN alfa-2a updates RSS · CI watch RSS
- Hoffmann-La Roche portfolio CI
Frequently asked questions about PEG-IFN alfa-2a
What is PEG-IFN alfa-2a?
PEG-IFN alfa-2a is a Small molecule drug developed by Hoffmann-La Roche.
Who makes PEG-IFN alfa-2a?
PEG-IFN alfa-2a is developed and marketed by Hoffmann-La Roche (see full Hoffmann-La Roche pipeline at /company/roche).
Is PEG-IFN alfa-2a also known as anything else?
PEG-IFN alfa-2a is also known as Pegasys, PEGASYS.
What development phase is PEG-IFN alfa-2a in?
PEG-IFN alfa-2a is FDA-approved (marketed).
Related
- Manufacturer: Hoffmann-La Roche — full pipeline
- Also known as: Pegasys, PEGASYS
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing